Could a diabetes drug help heart failure patients with valve replacements?
NCT ID NCT07610174
First seen May 27, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This study looked at whether adding semaglutide (a drug used for diabetes and weight loss) to the standard heart failure medication dapagliflozin helps people with heart failure who have had a surgical heart valve replacement. 160 participants were split into two groups: one got the combination therapy, the other continued dapagliflozin alone. Researchers tracked changes in heart function, symptoms, and quality of life to see if the combo offers extra benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kafrelsheikh univeristy hospital, Faculty of medicine, Kafrelsheikh univeristy
Kafr ash Shaykh, Kafrelsheikh Governrate, 33511, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If it works, this could point toward a new combination treatment to improve heart function and quality of life for heart failure patients with valve replacements.
What could go wrong
This is a small, early-phase proof-of-concept trial, so results may not be definitive. The combination may not provide additional benefit over standard care and could cause side effects like nausea or gastrointestinal issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.